Randomized Trialhigh evidence
Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract Gradients.
The American journal of cardiology·July 1, 2026·PMID 42002189
Why it mattersPatients with very-high LVOT gradients are at high risk for severe symptoms and often require invasive septal reduction. This analysis shows that aficamten can substantially lower gradients and improve functional status in this challenging subgroup, potentially delaying or avoiding surgery.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled